Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Multi-Cohort Trial of Combination Nivolumab and Temozolomide in Recurrent/Refractory Small-Cell Lung Cancer and Advanced Neuroendocrine Tumors

Trial Profile

A Phase II, Multi-Cohort Trial of Combination Nivolumab and Temozolomide in Recurrent/Refractory Small-Cell Lung Cancer and Advanced Neuroendocrine Tumors

Recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Jan 2019

At a glance

  • Drugs Nivolumab (Primary) ; Temozolomide (Primary)
  • Indications Neuroendocrine tumours; Small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Jan 2019 Status changed from not yet recruiting to recruiting.
    • 29 Nov 2018 Planned initiation date changed from 1 Nov 2018 to 1 Jan 2019.
    • 12 Nov 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top